Autoimmune hemolytic anemia (AIHA) after allogeneic hematopoietic stem cell transplantation (HSCT) is still not well characterized. The aim of this study was to analyze the incidence and risk factors for the development of AIHA, as well as its prognosis and response to treatment in a series of patients undergoing allogeneic HSCT at a single institution. Between 1996 and 2004, 272 adult patients with a variety of malignant hematopoietic disorders underwent allogeneic HSCT. Direct antiglobulin testing was performed in routine pretransfusion compatibility testing or after clinical suspicion of AIHA. Twelve patients developed AIHA after HSCT at a median time of 147 days (range, 41-170). The 3-year cumulative incidence of AIHA was 4.44%. Eight cold antibodies and four warm antibodies were detected. Multivariate analysis shows that HSCT from unrelated donors (P ¼ 0.02) and the development of chronic extensive graft-versus-host disease (GVHD) (P ¼ 0.0004) were the only independent factors associated with AIHA. Two patients are still alive. AIHA was never the primary cause of death but added morbidity in patients with other concomitant complications. Patients undergoing HSCT from unrelated donors and those who develop chronic extensive GVHD are especially predisposed for this complication.
Introduction
Immune-mediated hemolysis, alloimmune or autoimmune, is a well-recognized complication after allogeneic hematopoietic stem cell transplantation (HSCT). 1 The most common pathogenic mechanism is incompatibility in red blood cell (RBC) antigens, mainly of the ABO system, between donor and recipient leading to alloimmune hemolysis. 2 However, autoimmune hemolytic anemia (AIHA), defined as hemolysis owing to antibodies produced by the donor's immune system against donor red cell antigens, is more rarely observed after allogeneic HSCT.
AIHA after allogeneic HSCT has been associated with a variety of circumstances, such as chronic graft-versus-host disease (cGVHD), 3 T cell depletion 4 and unrelated donor transplants. 5 However, the incidence and risk factors for the development of AIHA, as well as its prognosis and response to treatment are still not well defined. In fact, our current knowledge of AIHA is based on single case reports [6] [7] [8] [9] and small series in adults 4, 10 and children. 5 The aim of the study was to analyze the characteristics of patients and transplants, as well as outcome, in a series of patients who developed AIHA after allogeneic HSCT at a single institution.
Patients and methods

Patients
Between January 1996 and June 2004, 272 consecutive adults underwent allogeneic HSCT for the treatment of a variety of malignant hematopoietic disorders at the University Hospital La Fe. Patient and transplant characteristics are shown in Table 1 .
Transplantation procedures
Conditioning regimens and selection of stem cell source varied according to diagnosis, donor availability and urgency of transplantation. The vast majority of patients received conditioning chemotherapy based on busulfan and cyclophosphamide with or without thiotepa and antithymocytic globulin. Subcutaneous filgrastim (Amgen, Thousand Oaks, CA, USA) was administered to all patients from day 7 after transplant in an attempt to shorten time to engraftment. For GVHD prophylaxis, recipients of non-T cell-depleted bone marrow or peripheral blood grafts received Cyclosporine A (CyA) and methotrexate, whereas recipients of T cell-depleted and cord-blood grafts received CyA and prednisone. Treatment of acute GVHD consisted of standard full dose (2 mg/kg) or high-dose methylprednisolone (20 mg/kg) in patients undergoing HSCT from related and unrelated donors, respectively. Antithymocyte globulin was administered as second-line therapy in refractory cases. Chimerism analysis was performed routinely on days 28, 100, 180 and 365 after HSCT, using fluorescence in situ hybridization or polymerase chain reaction techniques. Until June 2000, variable nucleotide tandem repeat markers were used as previously described. 11 Later, short tandem repeat (STR) markers were processed as follows: amplification was performed using the AmpF/STR SGM plus kit (Applied Biosystems, Foster City, CA, USA); amplified products were analyzed on the ABI Prism 310 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA); collected data were analyzed with GeneScan software, and automating genotyping of alleles was performed with Genotyper software (Applied Biosystems, Foster City, CA, USA).
Transfusion policy consisted of packed RBC and platelet units to maintain the hemoglobin level and platelet count above 8 g/dl and 10 Â 10 9 /l, respectively. Transfused blood products were irradiated to 1.5 Gy and filtered through white blood cell-reduction filters before transfusion. Prophylaxis against bacterial and fungal infections was systematically given with ciprofloxacin and fluconazole, respectively, and against Pneumocystis carinii-induced pneumonia with cotrimoxazole. Patients who were serologically positive for cytomegalovirus (CMV) before HSCT received prophylaxis with acyclovir from day 5 until engraftment, followed by ganciclovir. CMV-negative recipients were only given acyclovir for viral infection prophylaxis. Nonspecific intravenous immunoglobulin was administered weekly until day þ 100 and then monthly during the first year after transplant. Patients were monitored for CMV antigenemia by leukocyte expression of the CMV-pp65 antigen twice weekly until day þ 120, and once weekly from day þ 120 to þ 180.
Serologic tests ABO, Rh typing and RBC antibody screening tests were performed on donor and recipient samples before transplantation and whenever patients required transfusion of blood products, as described previously. 12, 13 The direct antiglobulin test (DAT) was performed in routine pretransfusion compatibility testing and in all patients with clinical suspicion of hemolytic anemia. The DAT was performed on RBCs from ethylenediaminetetraacetic acid samples using polyspecific antihuman globulin (Organon Teknika, Durham, NC, USA) according to standard methods.
14 When the DAT was positive, further testing with specific anti-IgG (IgG, Ortho Clinical Diagnostics, High Wycombe, Bucks, UK) and anti-C3d reagents (Biotest AG, Dreieich, Germany) was carried out. RBC eluates were prepared and tested by acid elution (Elu-Kitt II, Gamma Biologicals, Houston, TX, USA) or chloroform techniques. 15 Eluates and sera of patients with positive screening tests or positive DAT were tested for specificity and titration using panels of RBC with known antigens (Ortho Clinical and Diagnostics, Diamed and Makropanel), at room temperature and at 371C. Absorption techniques were performed to exclude any underlying alloantibody. The IgG and IgM components of the antibodies were determined by testing sera before and after treatment with dithiothreitol. 16 Patients who developed antibodies to RBC antigens, which were considered clinically significant received blood that was negative for the identified antigen only.
Definitions
AIHA was diagnosed in patients fulfilling all of the following criteria: (1) positive DAT, (2) positive indirect antiglobulin test (IAT) with broad reactivity to RBC in serum and eluate, (3) clinical and laboratory evidence of hemolysis (increase of LDH and bilirubin levels, decrease of hemoglobin and haptoglobin levels or increase in transfusion requirements), (4) other causes of immune hemolytic anemia had been excluded.
Acute and cGVHD were defined and graded according to standard criteria. [17] [18] [19] CMV infection was defined as any positivity of viral antigen pp65 in two or more cells at any time for which gancyclovir at a therapeutic dose was immediately started. If any signs or symptoms were present, CMV disease was diagnosed. Complete response to treatment for AIHA was defined as normalization of all clinical and laboratory signs of hemolysis and no detectable antibody in serum, eluate or on the red cell surface. Partial response was defined as presence of autoantibody with improvement of laboratory data or decrease in transfusion requirements.
Statistical analysis
The w 2 or Fisher exact tests were used for comparison of proportions. Unadjusted time-to-event analyses were performed using the Kaplan-Meier estimate. 20 The probability of developing AIHA was estimated by the cumulative incidence method (marginal probability). 21, 22 Death from causes other than AIHA was defined as competing risk. Patients who were alive and did not develop AIHA were censored. For the analysis of overall survival, all deaths from any cause were considered uncensored events, with any patient alive at last follow-up having been censored. To identify the most significant independent prognostic factors, all three variables achieving statistical significance on univariate analysis were included in additional multivariate analysis using the Cox model. 23 cGVHD was considered as a time-dependent variable. Patient follow-up was updated on December 31, 2005. All P-values reported are two-sided. Except for the cumulative incidence method, computations were performed using the BMDP statistical library (BMDP Statistical Software Inc., Los Angeles, CA, USA).
Results
Incidence of AIHA and patient characteristics All patients had a negative DAT before HSCT. Ninety-six patients had a positive DAT at any time after transplantation. AIHA was diagnosed in 12 patients who fulfilled the defined criteria (see definitions). The cumulative incidence of post-transplant AIHA at 3 years was 4.4%. Median time to diagnosis of AIHA after HSCT was 147 days (range, 41-170).
Risk factors for developing AIHA and patient characteristics are shown in Tables 2 and 3. All patients had complete donor chimerism at the time of onset of AIHA, with stable peripheral counts, and were in complete remission. Of the five patients who developed AIHA before day 100, four had acute GVHD grade III or IV. Of the seven patients with AIHA after day 100, six had concurrent chronic extensive GVHD.
Five patients had CMV reactivation and another patient gastrointestinal CMV disease and CMV retinitis, unresponsive to treatment. Other important comorbidities were also associated with AIHA: one patient had disseminated adenovirus; one developed disseminated tuberculosis infection concomitant with CMV reactivation; two patients had septic shock owing to Pseudomonas and Salmonella infection; one patient had life-threatening pneumonia without microbiological isolations. Two patients developed thrombocytopenia of suspected immune origin while suffering from AIHA. One patient with AIHA also developed pure red cell aplasia.
Serologic testing
All patients with AIHA had strongly positive DAT. The IAT was also positive both in serum and eluate, with broad specificity to a panel of commercial RBC. Eight patients developed AIHA by cold antibodies (IgM), whereas the remaining four had warm antibodies (IgG). All of them had clinical and laboratory signs of significant hemolysis. There was no association between time of appearance of AIHA and type of antibody. Major and minor donor-recipient incompatibility for the ABO system was present in two and one patients, respectively. The DAT test as well as the IAT was performed on donor and recipient before HSCT with negative results in all cases. No antibodies against the ABO system were found.
Prognostic factors
Overall. The following variables were significantly associated with a higher cumulative incidence of AIHA at 3 years on univariate analysis: unrelated donor vs familyrelated donor (9 vs 2.6%, P ¼ 0.02) (Figure 1 ), chronic extensive GVHD vs no chronic extensive GVHD (10.8 vs 1.6%, P ¼ 0.01) ( Figure 2 ) and human leukocyte antigen (HLA) mismatch vs HLA match 6/6 (7.9 vs 3.1%, P ¼ 0.04). There was also a higher cumulative incidence of AIHA in patients undergoing HSCT using umbilical cord blood vs peripheral blood (8.9 vs 2.5%, P ¼ 0.03). The rest of the variables analyzed did not show a statistically significant difference. These results, as well as the variables used in the multivariate analysis, are shown in Table 2 .
In the multivariate analysis performed in 262 patients, unrelated donor HSCT (RR 1.45; 95% confidence interval (CI) 1.05-1.99; P ¼ 0.02) and the development of chronic extensive GVHD (RR 12.17; 95% CI 96.56-1.54; P ¼ 0.018) were the only independent risk factors associated with AIHA.
Matched sibling HSCT. Only the development of chronic extensive GVHD was significantly associated with a higher cumulative incidence of AIHA at 3 years on univariate analysis (7.7 vs 0%, P ¼ 0.02). The remaining variables did not show a statistically significant association with AIHA. These results are shown in Table 4 .
Unrelated donor HSCT.
Results of the univariate analysis are shown in Table 4 . None of the variables was associated with an increased incidence of AIHA in HSCT from unrelated donors or in the subgroup of UCB-HSCT.
Treatment and outcome
Only two patients are alive. The remaining patients died, mainly owing to infection or GVHD, between 3 and 28 months after HSCT. AIHA was never the primary cause of death but added morbidity in patients with other concomitant complications. Most patients received steroids as primary treatment for AIHA with no response in the majority of cases. Two patients were treated with Rituximab and achieved partial response, with an improvement in transfusion requirements. 
Discussion
This study shows that AIHA is a relatively common complication after allogeneic HSCT for the treatment of hematological malignancies. Patients undergoing HSCT from unrelated donors and those who develop chronic extensive GVHD are at increased risk of AIHA.
In the present study, which is to date the largest series reported of AIHA in adult patients following allogeneic HSCT, several facts with potential impact on the observed incidence of AIHA should be taken into account and discussed: (1) unlike other studies, 4 ,10 the systematic use of the DAT test in our series, not only after clinical suspicion but also as part of routine pre-transfusion compatibility testing, could have increased the sensitivity of the study decreasing the possibility of missing cases with AIHA; (2) the stringent definition criteria for diagnosis of AIHA, requiring the presence of clinically significant hemolysis in addition to the defined laboratory criteria (see 'Definitions'), led to the exclusion of 85 patients with a positive DAT not fulfilling the remaining criteria. The incidence might have been higher if only serological data had been taken into account and (3) theoretically, some patients transferred back to their referring centers once they were transfusion independent and clinically stable could have developed non-severe AIHA that could have been unnoticed.
Time from transplantation to AIHA observed in the present study (median 5 months) was similar to that reported previously. 4, 5, 10 Although most patients (9 out of 12) developed AIHA during the first year after HSCT (five in the first 3 months), a quarter of them were diagnosed between 1 and 2 years after transplantation. We were not able to confirm the association described by Chen et al. 10 between cold antibodies with early AIHA and warm antibodies with late AIHA.
Compared with patients undergoing HSCT from an HLA-identical sibling, the incidence of AIHA was particularly increased in patients undergoing HSCT from unrelated donors. This association has not been previously reported in an adult population, but it has been recently recognized in a large series of pediatric patients. 4 In this latter series, all children with AIHA were among those undergoing HSCT from unrelated donors, whereas none of the 100 patients undergoing HSCT from a matched sibling donor developed this complication. We found that AIHA was more frequent but not restricted to patients undergoing HSCT from unrelated donors. It should be noted that the vast majority of HSCT recipients from unrelated donors in our series received umbilical cord blood as stem cell source (72%) with a disparity in 1-2 HLA antigens in more than 90% of them. Our data do not allow elucidation of the relative contribution of the HLA disparity and other potential factors such as the severe immunosuppression and delayed immune recovery, in the increased incidence of AIHA observed in this particular setting. Horn et al. 24 described a high incidence of AIHA (19.5%) in patients with severe combined immune deficiency undergoing one full haplotype mismatched HSCT with complete T-cell depletion. In contrast, we found no association between AIHA and ex vivo T-cell depletion.
The association found between AIHA and cGVHD is not surprising. GVHD is a cellular alloimmune reaction from donor lymphocytes leading to tissue damage and altered immune function. It has been shown that GVHD predisposes to autoimmune disorders. [25] [26] [27] [28] In fact, AIHA can even be a presenting sign of cGVHD. 8, 29 The mechanism by which allogeneic cellular activation leads to a humoral autoimmune disorder is unclear. It has also been suggested that CyA could impair development of immune tolerance in the post-transplant period and thus induce the development of autoimmune reactions. CyA was used for GVHD prophylaxis and/or treatment almost universally in patients of all series published to date, as well as in the present series. Therefore, the specific role of this drug could not be assessed.
Two patients developed immune thrombocytopenia concomitantly with AIHA. The development of Evans syndrome has been previously described after autologous 30 and allogeneic 31 HSCT. The appearance of multiple autoimmune disorders after transplantation suggests the impairment of regulatory mechanisms of the immune system.
The pretransplant serologic status of CMV in the recipient has also been associated with an increased probability of cGVHD 17, 32 and could potentially be associated with the development of autoimmune disorders. 33 This association could not be confirmed in the present study. Patients who developed AIHA after HSCT showed a poor outcome. Although in no case was AIHA the direct cause of death, it was strongly associated with other concomitant life-threatening complications. Both AIHA itself and the required reinforcement of immune suppressive therapy add morbidity to patients already in poor clinical condition, most of them with severe acute or chronic extensive GVHD. The high incidence of CMV infection/disease and other viral infections observed in the patients reported here with AIHA is probably associated with the impaired immune status.
A major limitation of the study was the inherent difficulty of analyzing prognostic factors for the development of an event when the number of events is low (only 12 events). Results of the analysis of prognostic factors should therefore be taken with caution and should be confirmed in prospective studies.
In conclusion, AIHA is a clinically significant complication after HSCT that contributes to morbidity, and possibly to mortality, of these critically ill patients. Patients undergoing HSCT from unrelated donors and those who develop chronic extensive GVHD are specially predisposed to this complication.
